Literature DB >> 21864182

Abiraterone and increased survival in metastatic prostate cancer.

Alfredo Berruti, Anna Pia, Massimo Terzolo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21864182     DOI： 10.1056/NEJMc1107198

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.

Authors:  Justin Guinney; Tao Wang; Teemu D Laajala; Kimberly Kanigel Winner; J Christopher Bare; Elias Chaibub Neto; Suleiman A Khan; Gopal Peddinti; Antti Airola; Tapio Pahikkala; Tuomas Mirtti; Thomas Yu; Brian M Bot; Liji Shen; Kald Abdallah; Thea Norman; Stephen Friend; Gustavo Stolovitzky; Howard Soule; Christopher J Sweeney; Charles J Ryan; Howard I Scher; Oliver Sartor; Yang Xie; Tero Aittokallio; Fang Liz Zhou; James C Costello
Journal:  Lancet Oncol       Date:  2016-11-16       Impact factor: 41.316

2.  In vitro Anticancer Effects of JI017 on Two Prostate Cancer Cell Lines Involve Endoplasmic Reticulum Stress Mediated by Elevated Levels of Reactive Oxygen Species.

Authors:  Min Jeong Kim; Jin Mo Ku; Se Hyang Hong; Hyo In Kim; Yun Young Kwon; Joon-Sang Park; Deok Hyun Jung; Yong Cheol Shin; Seong-Gyu Ko
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

Review 3.  Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer.

Authors:  Sara Campora; Eleonora Campazzi; Silvia Zanardi; Matteo Puntoni; Marco Piccininno; Arnoldo Piccardo; Mehrdad Shoushtari Zadeh Naseri; Carlotta Defferrari; Nicoletta Provinciali; Marilena Petrera; Domenico Marra; Ennio Biscaldi; Gian Carlo Antonucci; Damiano Ricci; Matteo Clavarezza; Alessandra Gennari; Alberto Gozza; Mauro D'Amico; Marco Mori; Andrea DeCensi
Journal:  Transl Oncol       Date:  2016-12       Impact factor: 4.243

Review 4.  MYC Deregulation in Primary Human Cancers.

Authors:  Manpreet Kalkat; Jason De Melo; Katherine Ashley Hickman; Corey Lourenco; Cornelia Redel; Diana Resetca; Aaliya Tamachi; William B Tu; Linda Z Penn
Journal:  Genes (Basel)       Date:  2017-05-25       Impact factor: 4.096

5.  Neutrophil-lymphocyte ratio is a predictor of prognosis in patients with castration-resistant prostate cancer: a meta-analysis.

Authors:  Zhun Wang; Shuanghe Peng; Hui Xie; Linpei Guo; Ning Jiang; Zhiqun Shang; Yuanjie Niu
Journal:  Cancer Manag Res       Date:  2018-09-17       Impact factor: 3.989

6.  Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation.

Authors:  Hua Xu; Yin Sun; Chi-Ping Huang; Bosen You; Dingwei Ye; Chawnshang Chang
Journal:  Cancers (Basel)       Date:  2020-03-30       Impact factor: 6.639

Review 7.  Prognostic role of chromogranin A in castration-resistant prostate cancer: A meta-analysis.

Authors:  Peng Hong; Run-Qi Guo; Gang Song; Kai-Wei Yang; Lei Zhang; Xue-Song Li; Kai Zhang; Li-Qun Zhou
Journal:  Asian J Androl       Date:  2018 Nov-Dec       Impact factor: 3.285

8.  Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis.

Authors:  Lugeng He; Hui Fang; Chao Chen; Yanqi Wu; Yuyong Wang; Hongwei Ge; Lili Wang; Yuehua Wan; Huadong He
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.